Takeda Seeks Biologics License for IBD Treatment

Takeda Pharmaceutical Company has submitted a biologics license application to the FDA for its Crohn’s disease and ulcerative colitis treatment vedolizumab, according to a Gastroenterology & Endoscopy News report.

Advertisement

Vedolizumab has been studied in 2,700 patients in nearly 40 different countries. It is designed to treat moderate to severe Crohn’s disease and ulcerative colitis.

More Articles on Gastroenterology:
MIT Researchers Develop 3-D Colonoscopy Technique
Florida Medical Association Names Dr. Alan Harmon President
New York Gastroenterology Associates Opens Scarsdale Office

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.